Biography

Dr. Sébastien Fortin

Faculty of Pharmacy

Université Laval, Canada

CHU de Québec Research Center, Canada

Assistant professor


Email: sebastien.fortin@pha.ulaval.ca


Qualifications

2010 Ph.D., Medicinal Chemistry, Université Laval, Canada

2010 Ph.D., Medicinal Chemistry, Université d’Auvergne 1, France

2005 M.Sc., Medicinal Chemistry, Université Laval, Canada

2003 B.Sc., Chemistry, Université Laval


Publications

  1. Chavez Alvarez, A. C., Bouzriba, C., Ouellette, V., Gagné-Boulet, M., Patenaude, A., Pilote, S., C.-Gaudreault, R., Simard, C., & Fortin, S. (2025). Toxicity, Half-Life and Antitumor Activity of Phenyl 4-(2-Oxo-3-alkylimidazolidin-1-yl)benzenesulfonates as Novel Antimitotic CYP1A1-Targeted Prodrugs in Female Mouse Models. Pharmaceutics, 17(2), 233. https://doi.org/10.3390/pharmaceutics17020233
  2. Alvarez, A., Bouzriba, C., Bernier, L. et al. Development of an UHPLC-UV Method for Quantification of Three Phenyl 4-(2-oxo-3-alkylimidazolidin-1-yl)benzenesulfonates in CD-1® IGS Female Mouse Plasma. J Anal Chem 79, 456–463 (2024). https://doi.org/10.1134/S1061934824040026
  3. Gagné-Boulet, M., Bouzriba, C., Chavez Alvarez, A. C., & Fortin, S. (2022). Preparation and biological evaluation of new antimicrotubule agents: Modification of the imidazolidin-2-one moiety of phenyl 4-(2-oxoimidazolidin-1-yl)benzenesulfonates. Chemical Biology & Drug Design, 99, 187–196. https://doi.org/10.1111/cbdd.13971
  4. Vincent Ouellette, Atziri Corin Chavez Alvarez, Sébastien Fortin; Abstract 284: Design, synthesis and biological evaluation of novel water-soluble salts of the antimitotic prodrugs 4-(3-alkyl-2-oxoimidazolidin-1-yl)-N-phenylbenzenesulfonamides selectively bioactivated by cytochrome p450 1A1 in breast cancer cells. Cancer Res 1 July 2021; 81 (13_Supplement): 284. https://doi.org/10.1158/1538-7445.AM2021-284
  5. Chahrazed Bouzriba, Atziri Corin Chavez Alvarez, Mathieu Gagné-Boulet, Jacques Lacroix, Marie-France Côté, René C.-Gaudrault, Sébastien Fortin; Abstract 285: Development of phenyl 4-(2-oxo-3-alkylimidazolidin-1-yl)benzenesulfonates as new antimitotic cytochrome P450 1A1-activated prodrugs selective toward breast cancers: Evaluation of branched alkyl chains. Cancer Res 1 July 2021; 81 (13_Supplement): 285. https://doi.org/10.1158/1538-7445.AM2021-285
  6. Atziri Corin Chavez Alvarez, Chahrazed Bouzriba, Mathieu Gagné-Boulet, Sylvie Pilote, René C.-Gaudreault, Chantale Simard, Sébastien Fortin; Abstract 1359: Evaluation of the therapeutic potential of AIMZ-938 as a new cytochrome p450 1A1-selective prodrug for the treatment of breast cancers. Cancer Res 1 July 2021; 81 (13_Supplement): 1359. https://doi.org/10.1158/1538-7445.AM2021-1359
  7. Mathieu Gagné-Boulet, Chahrazed Bouzriba, Atziri Corin Chavez Alvarez, Sébastien Fortin; Abstract 286: Conception and preparation of new potent antimicrotubule agents. Cancer Res 1 July 2021; 81 (13_Supplement): 286. https://doi.org/10.1158/1538-7445.AM2021-286
  8. Mitra Zarifi Khosroshahi, Atziri Corin Chavez Alvarez, Mathieu Gagné-Boulet, René C.-Gaudreault, Stéphane Gobeil, Sébastien Fortin, Evaluation of the time-dependent antiproliferative activity and liver microsome stability of 3 phenyl 4-(2-oxo-3-alkylimidazolidin-1-yl)benzenesulfonates as promising CYP1A1-dependent antimicrotubule prodrugs, Journal of Pharmacy and Pharmacology, Volume 72, Issue 2, February 2020, Pages 249–258, https://doi.org/10.1111/jphp.13198
  9. V. Denavit, D. Lainé, C. Bouzriba, E. Shanina, É. Gillon, S. Fortin, C. Rademacher, A. Imberty, D. Giguère, Stereoselective Synthesis of Fluorinated Galactopyranosides as Potential Molecular Probes for Galactophilic Proteins: Assessment of Monofluorogalactoside–LecA Interactions. Chem. Eur. J. 2019, 25, 4478.
  10. Couillard-Montminy V, Gagnon P-Y, Fortin S, Côté J. Effectiveness of adjuvant carboplatin-based chemotherapy compared to cisplatin in non-small cell lung cancer. Journal of Oncology Pharmacy Practice. 2017;25(1):44-51. doi:10.1177/1078155217724595
  11. P. M. Vadhadiya, M.-A. Jean, C. Bouzriba, T. Tremblay, P. Lagüe, S. Fortin, J. Boukouvalas, D. Giguère, Diversity-Oriented Synthesis of Diol-Based Peptidomimetics as Potential HIV Protease Inhibitors and Antitumor AgentsChemBioChem 2018, 19, 1779.
  12. Pauty, J., Côté, MF., Rodrigue, A. et al. Investigation of the DNA damage response to SFOM-0046, a new small-molecule drug inducing DNA double-strand breaks. Sci Rep 6, 23302 (2016). https://doi.org/10.1038/srep23302
  13. Mathieu Gagné-Boulet, Sébastien Fortin, Jacques Lacroix, Carole-Anne Lefebvre, Marie-France Côté, René C-Gaudreault; Abstract 1664: New moieties mimicking the trimethoxyphenyl (ring A) of combretastatin A-4: Synthesis and biological evaluation. Cancer Res 1 August 2015; 75 (15_Supplement): 1664. https://doi.org/10.1158/1538-7445.AM2015-1664
  14. Gagné-Boulet M., Fortin S., Lacroix J., Lefebvre C.-A., Côté M.-F. et C.-Gaudreault R. (2015), Styryl-N-phenyl-N'-(2-chloroethyl)ureas and styrylphenylimidazolidin-2-ones as new potent microtubule-disrupting agents using combretastatin A-4 as model, European Journal of Medicinal Chemistry, 100, 34-43.
  15. Fortin S., Wei L., P. Kotra L. and C.-Gaudreault R. (2015), Novel cytocidal substituted phenyl 4-(2-oxoimidazolidin-1-yl)benzenesulfonates and benzenesulfonamides with affinity to the colchicine-binding site: is the phenyl 2-imidazolidinone moiety a new haptophore for the design of new antimitotics?, Open Journal of Medicinal Chemistry, 5, 9-22.
  16. Morin N., Bruneau J., Fortin S., Brasseur K., Leblanc V., Asselin É. and Bérubé G. (2015), New testosterone derivatives as semi-synthetic anticancer agents against prostate cancer: synthesis and preliminary biological evaluation, Medicinal Chemistry, 11, 1-9.
  17. Fortin S., Brasseur K., Morin N., Asselin É. and Bérubé G. (2013), New platinum(II) complexes conjugate at position 7α of 17β-acetyl-testosterone as new combi-molecules against prostate cancer: Design, synthesis, structure-activity relationships and biological evaluation, European Journal of Medicinal Chemistry, 68, 433-443.
  18. Marceau F., Bouthillier J., Houle S., Sabourin T., Fortin J.-P., Morissette G., Lodge R., Fortin S., C.-Gaudreault R., Bawolak M.-T., Koumbadinga G. A., Roy C., Charest-Morin X. and Gera L. (2013), Bradykinin receptors: agonists, antagonists, expression, signaling and adaptation to sustained stimulation, Journal of Angioedema, 1, 9-17.
  19. Charest-Morin X., Fortin S., Lodge R., Roy C., Gera L., C.-Gaudreault R. and Marceau F. (2013), Inhibitory effects of cytoskeleton disrupting drugs and GDP-locked Rab mutants on bradykinin B2 receptor cycling, Pharmacological Research, 71, 44-52.
  20. Saha P., Fortin S., Leblanc V., Asselin É. and Bérubé G. (2012), Design, synthesis, cytocidal activity and estrogen receptor α affinity of doxorubicin conjugates at 16α-position of estrogen for site-specific treatment of estrogen receptor-positive breast cancers, Steroids, 77, 1113-1122.


Profile Details

https://www.pha.ulaval.ca/faculte/repertoire-du-personnel/sebastien-fortin

Free SCIRP Newsletters
Copyright © 2006-2025 Scientific Research Publishing Inc. All Rights Reserved.
Top